KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-cash Items (2016 - 2025)

Acadia Pharmaceuticals has reported Non-cash Items over the past 15 years, most recently at $79.3 million for Q4 2025.

  • Quarterly results put Non-cash Items at $79.3 million for Q4 2025, up 1032.92% from a year ago — trailing twelve months through Dec 2025 was $79.3 million (up 1032.92% YoY), and the annual figure for FY2025 was $79.3 million, up 1032.92%.
  • Non-cash Items for Q4 2025 was $79.3 million at Acadia Pharmaceuticals, up from $7.0 million in the prior quarter.
  • Over the last five years, Non-cash Items for ACAD hit a ceiling of $91.0 million in Q4 2023 and a floor of $1.1 million in Q4 2022.
  • Median Non-cash Items over the past 5 years was $16.4 million (2021), compared with a mean of $38.9 million.
  • Biggest five-year swings in Non-cash Items: crashed 95.67% in 2021 and later soared 8546.58% in 2023.
  • Acadia Pharmaceuticals' Non-cash Items stood at $16.4 million in 2021, then crashed by 93.59% to $1.1 million in 2022, then soared by 8546.58% to $91.0 million in 2023, then tumbled by 92.31% to $7.0 million in 2024, then skyrocketed by 1032.92% to $79.3 million in 2025.
  • The last three reported values for Non-cash Items were $79.3 million (Q4 2025), $7.0 million (Q4 2024), and $91.0 million (Q4 2023) per Business Quant data.